Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue

scientific article published in November 2002

Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0041-1345(02)03502-9
P698PubMed publication ID12431671

P50authorStanislava Stosic-GrujicicQ39271755
Danijela Maksimović-IvanićQ39272047
Miodrag L LukicQ63676154
P2093author name stringD Miljkovic
M Mostarica Stojkovic
V Trajkovic
P2860cites workPentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetesQ28344783
Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production.Q32061593
Mycophenolate mofetil and its mechanisms of actionQ33957177
Type I diabetes mellitus. A chronic autoimmune diseaseQ34181699
Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin modelQ71197849
Mycophenolate mofetil can prevent the development of diabetes in BB ratsQ72246392
P433issue7
P407language of work or nameEnglishQ1860
P304page(s)2955-2957
P577publication date2002-11-01
P1433published inTransplantation ProceedingsQ7834825
P1476titleInhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue
P478volume34

Reverse relations

cites work (P2860)
Q39032639From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Q28551762In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes
Q57839861Mycophenolate mofetil and animal models
Q45113442Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
Q37160327The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes

Search more.